Undisclosed programs RD neurology conditions, eye conditions
Kriya Therapeutics is developing gene therapies for ophthalmology, neurology and metabolic diseases. Despite diversifying to various disease indications, Kriya is using the same principles to create accessible, specific and effective one-time gene therapies to address common diseases. Kriya’s lead compounds across ophthalmology, neurology and metabolic are all currently in preclinical stages and are employing adeno-associated viruses (AAV) as their delivery modality. For example, Kriya’s approach to treat dry age-related macular degeneration, KRIYA-825, is an AAV gene therapy that encodes a fusion protein to inhibit complement C3 and C5, with the aim of slowing lesion growth and vision loss.